Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Touchlight Expands mbDNA Platform | Contract Pharma

What are you searching for?

Sign in
Breaking News

Touchlight Expands mbDNA Platform

Introduces three new circular DNA architectures.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Touchlight, a provider of cell-free DNA technology, has expanded its mbDNA platform with the introduction of three new circular DNA architectures: sscDNA, hsscDNA, and dscDNA. These constructs join mbDNA, which debuted earlier this year, to form a comprehensive portfolio designed to overcome the limitations of traditional gene editing tools.

The mbDNA platform and new custom circle DNA architectures deliver enhanced stability, reduced immunogenicity, and compatibility with a broad range of gene insertion and expression technologies, setting a new standard for precision and performance in genetic engineering.

The flexible nature of Touchlight’s novel circular DNA molecules allows for bespoke designs to optimize gene therapy platforms that utilize DNA payloads for episomal expression or integration. sscDNA is a fully single-stranded circular DNA molecule, whereas hsscDNA contains bespoke double stranded region(s) of user-defined length. dscDNA is a fully double stranded circular molecule. The sequence of all DNA constructs is completely user defined and ideal for transposases, recombinases, HITI, and episomal expression.

“mbDNA is a market leading technology providing the best-in-class HDR template available today,” said Karen Fallen, CEO at Touchlight. “With the addition of sscDNA, hsscDNA, and dscDNA, we’re empowering researchers and developers to unlock new possibilities in gene editing and therapeutic innovation.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics